Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNMT1 Facilitates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease [snRNA-Seq]

ABSTRACT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by notable epigenetic changes, such as alterations in DNA methylation. However, research on epigenetic modifications in human patient and animal models remains sparse. This study investigates the role of DNMT1 in MASLD progression. DNMT1 inhibition restores DNA methylation patterns and transcriptional activity, suggesting it as a potential therapeutic target for MASLD.

ORGANISM(S): Mus musculus

PROVIDER: GSE285014 | GEO | 2026/08/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

DNMT1 Facilitates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease

Project description:Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by notable epigenetic changes, such as alterations in DNA methylation. However, research on epigenetic modifications in human patient and animal models remains sparse. This study investigates the role of DNMT1 in MASLD progression. DNMT1 inhibition restores DNA methylation patterns and transcriptional activity, suggesting it as a potential therapeutic target for MASLD.

2026-08-12 | GSE283953 | GEO

DNMT1 Facilitates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease [RNA-seq]

2026-08-12 | GSE284446 | GEO

DNMT1 Facilitates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease [ChIP-seq]

2026-08-12 | GSE284617 | GEO

RNA-seq data of primary human hepatocytes spheroids from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) donors following troglitazone treatment

Project description:Primary human hepatocytes from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) patients (6 donors each) as 3D spheroids treated with troglitazone (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Data for Figure 5 in connected publication.

2026-01-16 | E-MTAB-15610 | biostudies-arrayexpress

Dnmt1 has de novo activity targeted to transposable elements

Project description:DNA methylation plays a critical role in development, particularly in repressing retrotransposons. The mammalian methylation landscape is dependent on the combined activities of the canonical maintenance enzyme Dnmt1 and the de novo Dnmts, 3a and 3b. Here we demonstrate that Dnmt1 displays de novo methylation activity in vitro and in vivo with specific retrotransposon targeting. We used whole-genome bisulfite and long-read Nanopore sequencing in genetically engineered methylation depleted embryonic stem cells to provide an in-depth assessment and quantification of this activity. Utilizing additional knockout lines and molecular characterization, we show that Dnmt1's de novo methylation activity depends on Uhrf1 and its genomic recruitment overlaps with targets that enrich for Trim28 and H3K9 trimethylation. Our data demonstrate that Dnmt1 can de novo add and maintain DNA methylation, especially at retrotransposons and that this mechanism may provide additional stability for long-term repression and epigenetic propagation throughout development.

2021-06-29 | PXD025736 | Pride

Single nucleus chromatin accessibility Profiling on the human metabolic dysfunction associated steatotic liver disease samples

Project description:Single-nucleus Assay for Transposase-Accessible Chromatin with sequencing (snATAC-seq) in human mapping of chromatin accessibility in specific cell clusters profiled alterations in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) samples compared to normal controls, providing insights into cell-type-specific epigenetic changes associated with MASLD.

2026-03-16 | GSE281367 | GEO

DNMT1 Facilitates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease [snRNA-Seq]

Project description:DNMT1 Facilitates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease [snRNA-Seq]

| PRJNA1200809 | ENA

Deep proteome profiling of metabolic dysfunction-associated steatotic liver disease

Project description:Analyze human biopsies for the investigation of metabolic dysfunction-associated steatotic liver disease (MASLD). We also analyzed plasma samples for biomarker discovery. And analyzed the role of the impact of the adipose tissue on plasma proteins in relation to MASLD

2025-03-05 | PXD051911 | Pride

Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) [MouseMethylation]

Project description:Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is a growing epidemic with an estimated prevalence of 20‑30% in Europe and the most common cause of chronic liver disease worldwide. The onset and progression of MASLD are orchestrated by an interplay of the metabolic environment with genetic and epigenetic factors. Emerging evidence suggests altered DNA methylation pattern as a major determinant of MASLD pathogenesis coinciding with progressive DNA hypermethylation and gene silencing of the liver‑specific nuclear receptor PPARα, a key regulator of lipid metabolism. To investigate how PPARα loss of function contributes to epigenetic dysregulation in MASLD pathology, we studied DNA methylation changes in liver biopsies of WT and hepatocyte‑specific PPARα KO mice, following a 6‑week CDAHFD (choline-deficient, L-amino acid-defined, high-fat diet) or chow diet. Interestingly, genetic loss of PPARα function in hepatocyte‑specific KO mice could be phenocopied by a 6-week CDAHFD diet in WT mice which promotes epigenetic silencing of PPARα function via DNA hypermethylation, similar to MASLD pathology. Remarkably, genetic and lipid diet‑induced loss of PPARα function triggers compensatory activation of multiple lipid sensing transcription factors and epigenetic writer-eraser-reader proteins, which promotes the epigenetic transition from lipid metabolic stress towards ferroptosis and pyroptosis lipid hepatoxicity pathways associated with advanced MASLD. In conclusion, we show that PPARα function is essential to support lipid homeostasis and to suppress the epigenetic progression of ferroptosis‑pyroptosis lipid damage associated pathways towards MASLD fibrosis.

2024-03-01 | GSE238173 | GEO

NSD2 aggravates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway

Project description:Extensive research has demonstrated that impaired autophagy contributes to the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Qiao et al. identified NSD2 in the liver as a novel and essential regulator of MASLD. NSD2 epigenetically represses TFEB transcription through trimethylation of histone H4 at lysine 20 (H4K20me3), thereby impairing autophagic flux to exacerbate hepatic steatosis. In conclusion, NSD2 functions as a crucial epigenetic regulator of impaired autophagic flux in the liver, offering a novel therapeutic target for MASLD management.

2026-01-01 | GSE287554 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data